Conatus Pharmaceuticals Inc (NASDAQ:CNAT) was the target of a large drop in short interest during the month of July. As of July 15th, there was short interest totalling 2,044,100 shares, a drop of 26.5% from the June 15th total of 2,780,300 shares. Approximately 7.8% of the company’s shares are short sold. Based on an average daily volume of 936,600 shares, the short-interest ratio is currently 2.2 days.

Separately, HC Wainwright reaffirmed a “buy” rating on shares of Ballard Power Systems in a research note on Friday, May 3rd. One analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $5.12.

Shares of CNAT stock remained flat at $$0.31 on Friday. The company had a trading volume of 242,919 shares, compared to its average volume of 1,427,670. Conatus Pharmaceuticals has a 52-week low of $0.25 and a 52-week high of $6.74. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.40 and a quick ratio of 2.40. The business’s 50 day moving average is $0.50.

Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.02). Conatus Pharmaceuticals had a negative return on equity of 81.02% and a negative net margin of 57.46%. The business had revenue of $7.02 million for the quarter, compared to the consensus estimate of $8.26 million. On average, equities research analysts anticipate that Conatus Pharmaceuticals will post -0.48 earnings per share for the current fiscal year.

Several hedge funds have recently modified their holdings of the stock. D. E. Shaw & Co. Inc. lifted its stake in shares of Conatus Pharmaceuticals by 50.4% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 62,163 shares of the biotechnology company’s stock worth $108,000 after acquiring an additional 20,826 shares during the last quarter. Hikari Power Ltd lifted its stake in shares of Conatus Pharmaceuticals by 19.8% during the 1st quarter. Hikari Power Ltd now owns 200,488 shares of the biotechnology company’s stock worth $217,000 after acquiring an additional 33,200 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Conatus Pharmaceuticals by 19.4% during the 4th quarter. Geode Capital Management LLC now owns 208,346 shares of the biotechnology company’s stock worth $360,000 after acquiring an additional 33,827 shares during the last quarter. Wedbush Securities Inc. bought a new stake in shares of Conatus Pharmaceuticals during the 1st quarter worth approximately $46,000. Finally, Acadian Asset Management LLC lifted its stake in shares of Conatus Pharmaceuticals by 60.1% during the 1st quarter. Acadian Asset Management LLC now owns 245,078 shares of the biotechnology company’s stock worth $265,000 after acquiring an additional 91,956 shares during the last quarter. 25.54% of the stock is owned by hedge funds and other institutional investors.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Further Reading: What is the CBOE Russell 2000® Volatility Index?

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.